



VACCINE RESEARCH PORTFOLIO

**ADVANCING PREVENTIVE CARE
THROUGH CLINICAL RESEARCH**



MAZHAR JAFFRY

MBBS, MBA, MHA

32+ YEARS

OF EXPERIENCE IN HEALTHCARE
LEADERSHIP

CHAMPION OF INNOVATION,
DIVERSITY & PATIENT CENTRIC CARE

MESSAGE FROM THE CEO

HELLO & WELCOME,



As CEO of Revival Research Site Network, I am proud to present this portfolio, which highlights our shared commitment to redefining clinical research and patient care—one clinical trial at a time.

Revival Research Site Network combines innovation, operational excellence, and compassionate patient care to set a new standard in clinical research. Driven by a pioneering spirit, we lead the way with robust infrastructure, streamlined processes, and precise execution, demonstrating that excellence is not just a goal, but a practice woven into everything we do.

As we look to the future, our collective vision remains focused on leading the way in clinical research, constantly evolving to meet the challenges of this dynamic field.

We are excited about the opportunities that lie ahead for Revival Research Site Network.

Thank you for being an integral part of our journey and for joining us as we continue to make strides in clinical research and patient care. With each milestone, we reaffirm our promise to uphold the highest standards of ethics, innovation, and collaboration. We remain devoted to inclusivity and patient-centricity in everything we do. As we grow, we will keep striving to create lasting impact, within the industry.

COMPANY OVERVIEW

Revival Research Site Network is an integrated research site network, committed to providing patient-centric clinical trials, quality care to patients, and catering to the diverse patient population. Our focus is on optimizing and streamlining processes through the integration of innovative technologies, aiming to minimize risks while conducting efficient trials for our sponsors.



We prioritize tailoring our strategies to meet the unique requirements of each clinical trial, ensuring strict compliance with study protocols and timely regulatory submissions. Central to our approach is transparent communication, which fosters open channels for all stakeholders, especially concerning patient safety and data integrity.



Building Strong Partnerships for Better Clinical Trial Outcomes

We emphasize fostering strong partnerships with healthcare providers and research institutions, allowing us to expand our reach and access diverse patient populations. This collaboration drives better trial outcomes and contributes to advancing medical knowledge.

Driving Efficiency & Innovation in Patient-centric Clinical Research

Our reliable and predictable processes enable us to meet critical milestones faster than the industry average. We leverage real-world insights and research expertise to develop patient-centric solutions in clinical research that can be effectively implemented on a larger scale.



MISSION

Revival Research Site Network aims to transform healthcare with cutting-edge research studies, focusing on safety, innovation, and quality.

Our mission is to ethically advance medicine by conducting rigorous and groundbreaking clinical trials. As a trusted and reliable partner in healthcare, we strive to improve lives by ensuring the highest standards in our clinical trials, fostering a culture of excellence, and pushing the boundaries of medical knowledge. We are committed to collaborating with healthcare professionals, patients, and stakeholders to deliver impactful solutions and make a lasting difference in the medical field.



VISION

Revival Research Site Network envisions transforming healthcare by collaborating with top pharmaceuticals, leveraging our experts' knowledge to democratize clinical trials and fast-track the accessibility of life-changing therapies.

By fostering strong partnerships with leading industry players and utilizing the expertise of our dedicated team, we aim to streamline the clinical trial process, making it more inclusive and efficient. Our goal is to ensure that groundbreaking treatments and therapies are available to all who need them, regardless of their background or circumstances. Through our approach and commitment to excellence, we are changing the landscape of clinical research and improving health outcomes on a global scale.

WHAT WE DO: ADVANCING RESEARCH, ENHANCING CARE

At Revival Research Site Network, we provide comprehensive clinical trial services across multiple therapeutic areas, designed to accelerate drug and device development while keeping patient care at the heart of every study.



OUR SERVICES INCLUDE:



Clinical Trial Management

Full-service coordination from site selection to close-out, ensuring compliance, quality, and efficiency.



Patient Recruitment & Retention

Proven strategies to engage diverse populations and ensure continuity throughout the study lifecycle.



Therapeutic Expertise

Conducting Phase I-IV trials across a range of conditions including cardiology, endocrinology, psychiatry, pulmonology, infectious diseases, and more.



Regulatory & Compliance Support

Navigating complex regulatory environments with precision and proactive oversight.



Outpatient-Based Studies

Offering convenience and accessibility for participants, while maintaining high standards of data integrity and patient safety.



Data Collection & Management

Using advanced technologies for accurate, real-time data capture and reporting.

WHO WE ARE

PIONEERING RESEARCH WITH COMPASSION

We are a multi-disciplinary, outpatient Clinical Research Site Network dedicated to advancing medical science through innovation, integrity, and a patient-first mindset. With a passionate team of experienced investigators and research professionals, we deliver integrated solutions tailored to the evolving needs of sponsors, partners, and patients alike.

Our collaborative approach bridges clinical expertise with cutting-edge research capabilities, ensuring every study is executed with precision, care, and transparency. From early-phase trials to late-stage studies, we are committed to making meaningful contributions to healthcare—while always prioritizing the well-being and experience of our participants.



OUR PILLARS

FAST STUDY START-UP



As a clinical research site network, we streamline study start-up to activate sites quickly and begin enrollment without delays. By accelerating contracts, ethics approvals, and site initiations, our experienced team shortens timelines and ensures trial readiness—helping sponsors meet deadlines and deliver therapies to patients faster.

HIGHEST PATIENT RECRUITMENT

We use strategic, multi-channel recruitment to achieve high enrollment rates and diverse participant pools.

Our approach ensures timely enrollment and strong retention throughout the study.



QUERY-FREE DATA



At Revival Research Site Network, we deliver query-free data through rigorous review and verification, ensuring accuracy, compliance, and the highest quality standards. This leads to fewer delays and a faster path to approval.

THERAPEUTIC AREAS



Nephrology



Cardiology



Covid-19



Dermatology



Oncology



Neurology



Allergy Medicine



Pain Management



Vaccine Studies




Women's Health



Internal Medicine

Robust Patient Enrollment Metrics

Over the years, we've consistently demonstrated strong and efficient patient enrollment strategies for our clinical trials. Our historic enrollment metrics underscore our commitment to expediency without compromising quality. Detailed percentages further highlight our proficiency in this domain.



- 92.0% — Met/Exceeded Enrollment Targets
- 96.0% — Retention Rate
- 51.0% — Enrollment within first 2 Months
- 33.0% — Diversity Enrollment Metrics
- 98.0% — Patient Satisfaction Score

OUR SITE NETWORK SETUP IN THE STATES

Revival Research Site Network is actively working towards expanding and increasing access to clinical research in various locations across the States. Our primary objective is to make clinical trials readily available to the local population of diverse communities. To achieve this, we have formed strong collaborations with experienced and diverse healthcare professionals, as well as organizations including **Accountable Care Organizations (ACO)** and **Healthcare Networks** that provide us with top-notch Principal Investigators and patient populations in need of clinical trials.

Through these partnerships, we strive to ensure that our clinical trials are conducted with the utmost care and precision, delivering valuable insights and potential therapies for the benefit of the communities we serve in the States.



Our PIs work as independent contractors



30+ Principal Investigators & 27 Sub-Investigators throughout the States




Over 15+ sites interspersed throughout the States
Michigan, Texas, Nebraska, Georgia, Illinois & North Carolina

DIVERSITY IN PIs, PATIENTS & SITE STAFF



ADVOCATING FOR DIVERSITY FROM WITHIN

Diversity is deeply embedded in the fabric of our organization at Revival. A remarkable 71% of our workforce represents a rich tapestry of backgrounds and cultures. Our CEO, a Pakistani American with a 31-year legacy in clinical research, sets the foundation for our inclusive values.



From our Principal Investigators to our clinical staff and community liaisons, we take immense pride in the diverse representation from African American, Indian, and Arab communities. This diverse mosaic not only brings unique perspectives to our work but also strengthens our ability to authentically connect with a wide range of patients.

Such diversity within our team positions us to attract and relate to a broad spectrum of patients in our clinical trials.

Vaccine Research

At Revival Research Site Network, we've consistently demonstrated our strength in conducting high-performance vaccine trials. With a focus on public health impact and operational excellence, our site network has contributed to the successful execution of several key studies in the vaccine space. From enrolling hundreds of participants to exceeding sponsor expectations, our work reflects a deep commitment to advancing preventive care through clinical research.



KEY HIGHLIGHTS:

- Successfully conducted vaccine trials for **COVID-19, Influenza, and C. Diff.**
- Enrolled a total of **1000+** patients across various vaccine studies.
- **302** Patients were enrolled within a week for Pfizer flu vaccine study.
- Achieved **200% enrollment goal** for the **C. Diff vaccine** study.
- Met **150% enrollment goal** for the **Flu vaccine** study.
- Currently **generating over 500 new leads per week** for upcoming vaccine trials.

EXPERIENCE IN SIMILAR FAST-PACED CLINICAL TRIALS FOR HEALTHY VOLUNTEERS



As a seasoned Clinical Research Organization, we specialize in delivering high-quality results under tight timelines. Our team is uniquely equipped to navigate the demands of accelerated clinical trials without compromising the scientific integrity or regulatory compliance required for successful study outcomes.

ECHO-004 KOSMOS TRIO & EJECTION FRACTION PIVOTAL STUDY



WHAT ? WE DID ?

- **Rapid Response:** Stepped in as the new study site after a last-minute change and fully onboarded within days.
- **Expert Training:** Trained staff on the Kosmos device to capture specific cardiac views.
- **Collaborative Approach:** Maintained clear, consistent communication with EchoNous throughout the process.

ENROLLMENT GOAL METRICS

Randomized 154 patients within a compressed timeline to meet a critical FDA submission deadline.

HOW WE ? DELIVERED ?

Driven by a “can-do” attitude and a hands-on approach, our team worked tirelessly to ensure the study’s success, balancing speed with precision every step of the way.

FROM CHALLENGE TO SUCCESS: ECHONOUS' JOURNEY WITH OUR NETWORK

“

Dear Revival Team,

We would like to express our sincere gratitude for the outstanding work of the Revival team in Dearborn, Michigan, in completing our ECHO-004 KOSMOS TRIO AND EJECTION FRACTION PIVOTAL STUDY. This study was critical for FDA clearance to continue the sale of our Kosmos System, an AI-assisted EKG/ultrasound device.

After unexpectedly losing our original study site in the summer of 2023, Revival stepped in with a “can-do” attitude and mobilized quickly to meet a tight FDA deadline. The task was complex, requiring the training of Revival staff on Kosmos and achieving specific cardiac views — yet your team handled it with professionalism, efficiency, and remarkable dedication, even finishing ahead of schedule.

Without your tireless effort, EchoNous would not have met the FDA deadline, which would have impacted our product rollout and sales. We are deeply grateful to the Revival team for making this critical project a success.

Thank you!

”

Rebecca L Penn
R.P, General Counsel



PREVENTIVE ALZHEIMER'S STUDY: STEADY PROGRESS IN SPECIALIZED RECRUITMENT

In our ongoing work on the Preventive Alzheimer's clinical trial, our team is focused on identifying and enrolling patients at risk of developing Alzheimer's, an area that requires both sensitivity and strategic outreach.

ENROLLMENT GOAL METRICS

- 2046+ enrollment goal were met.
- Enrollment completed within first month.
- Enrolled first patient globally.

WHAT WE'RE DOING

- **Focused Outreach:** Leveraging community partnerships and targeted outreach to identify eligible at-risk individuals.
- **Pre-Screening Precision:** Implementing careful and compliant screening procedures to ensure only the most appropriate candidates are enrolled.
- **Patient-Centered Approach:** Supporting patients through the process with personalized communication, flexibility, and education about the study's preventive goals.

This early progress reflects our commitment to excellence in even the most challenging therapeutic areas and positions the study for full enrollment and timely completion.

”



BAYER'S EXPERIENCE WITH US

Extending a heartfelt thank you to your site for the hard work and dedication in contributing Hispanic patient inclusion Diversity Randomizations.

Dear Dr. Owens and Team,

The US Team at Bayer would like to extend a heartfelt thank you to your site for the hard work and dedication in contributing to Hispanic Patient Inclusion Diversity Randomizations over the past week! Your hard work is noticed and recognized!

THANK YOU!

OCEANIC-AF Team



STRATEGIC SITE CAPABILITIES FOR VACCINE STUDIES

In addition to our strong enrollment metrics, our sites are well-equipped to support large-scale vaccine clinical trials. These high-capacity locations enable us to reach a wide and diverse patient population efficiently.

KEY SITE LOCATIONS & DAILY PATIENT CAPACITY:

- **Dr. Talib Raza (Southfield)**

Patient Capacity: Up to 200 patients per day

Strengths: High volume, established infrastructure, experienced staff

We have the capacity to accommodate up to 1,000 patients per week.

- **Dr. Abdul Hasan Saad (Dearborn)**

Patient Capacity: Up to 60 patients per day

Strengths: Consistent throughput, urban catchment area

We have the capacity to accommodate up to 300 patients per week.

- **Dr. Asad Karim's Site (Sherman)**

Very remote area. Strong connection with the people

Patient Capacity: Up to 40 patients per day

Strengths: Personalized care, diverse patient demographics

We have the capacity to accommodate up to 200 patients per week.

Revival Research Site Network can accommodate up to 6,000 patients per month across high-capacity, strategically located sites, enabling rapid, high-quality, and scalable support for vaccine studies.



**SYED
TALIB RAZA, M.D.
35+ YEARS
YEARS OF EXPERIENCE**

SPECIALITY: PULMONOLOGY & SLEEP MEDICINE

Dr. Syed Talib Raza is a seasoned Pulmonary and Sleep Disorder specialist based in Riverview, Michigan, with over 35 years of clinical experience and four board certifications. He is highly skilled in diagnosing and treating complex respiratory conditions including COPD, asthma, sleep apnea, and autoimmune disorders. Dr. Raza is known for his compassionate, patient-centric approach and commitment to clinical excellence. He brings more than two decades of clinical excellence to Revival Research Site Network's vaccine research initiatives and plays a crucial role in advancing studies focused on preventive care through innovative vaccine trials.

With a strong foundation in respiratory medicine, his extensive experience managing complex conditions such as COPD and severe asthma positions him uniquely to lead vaccine studies aimed at improving outcomes for at-risk patient populations. Driven by a patient-centered philosophy, Dr. Raza ensures that every clinical trial under his leadership prioritizes safety, scientific rigor, and accessibility.

VACCINE RESEARCH FOCUS

Dr. Raza has participated in and led a broad range of clinical trials that contribute directly to vaccine development efforts, including:

- Respiratory vaccine research targeting Chronic Obstructive Pulmonary Disease (COPD) and Asthma.
- Preventive vaccine initiatives for infectious respiratory diseases.
- Critical care and pulmonary studies that inform vaccine efficacy and safety strategies.
- Studies involving biologics that intersect with immunological pathways critical to vaccine response.

His background leading multi-center Phase II-IV trials has honed his ability to manage accelerated timelines and regulatory complexities, making him a key asset in high-performance vaccine trials.

EDUCATION & TRAINING

Dow Medical College, Karachi, Pakistan
MBBS, 1988

Muhlenberg Regional Medical Center (UMDNJ), NJ
Internal Medicine Residency, 1995

University of South Alabama
Fellowship in Pulmonary & Sleep Medicine, 1998

Diplomate, American Board of Internal Medicine
Pulmonary Disease, 2019

BOARD CERTIFICATIONS

American Board of Internal Medicine

American Board of Critical Care Medicine

American Board of Sleep Medicine

RESEARCH & ACADEMIC LEADERSHIP

Clinical Assistant Professor of Medicine

Director of Sleep Medicine, Michigan State University

Critical Care Medicine, Oakwood Hospital

Fellow of the American College of Chest Physicians

At Revival Research Site Network, Dr. Raza spearheads vaccine clinical trials, particularly in populations with underlying pulmonary conditions - groups often underrepresented yet most vulnerable. His leadership in respiratory vaccine studies supports the Institute's mission to fast-track life-saving therapies while maintaining a deep commitment to patient safety, data integrity, and community health.

Through his vaccine research efforts, Dr. Raza continues to advance preventive medicine and ensure broader access to cutting-edge clinical innovations.

PRINCIPAL INVESTIGATORS FOR VACCINE TRIALS

ABDULHASSAN SAAD, M.D.

INTERNAL MEDICINE, OBESITY MEDICINE & COVID-19
YEARS OF EXPERIENCE: 10+ YEARS



DR. SAAD'S BACKGROUND & EXPERIENCE

Born and raised in Dearborn, Michigan, Dr. Abdulhassan Saad has a passion for making healthcare accessible to communities. After completing his residency from William Beaumont School of Medicine, Dr. Saad worked in a hospital for 2 years before deciding to open up a primary practice in his hometown of Dearborn.

Dr. Saad is a triple board-certified doctor specializing in Internal Medicine, Obesity Medicine, COVID-19, and Addiction Medicine. Along with providing primary care services at his full-service practice, Dr. Saad also specializes in addiction treatment and management. His expertise in Internal Medicine alone makes him an integral part of our Principal Investigators network at Revival Research Site Network. Dr. Saad oversees Phase 2, 3, and 4 clinical trials on COVID-19 and various other Internal Medicine indications including Obesity Medicine.

CLINICAL RESEARCH & COMMUNITY IMPACT

Dr. Saad has been closely involved with clinical research, partnering with Revival Research Site Network since the peak of the COVID-19 pandemic. He has become a top national medical leader in COVID-19 clinical trials, demonstrating his commitment to improving public knowledge and patient care. His facility is fully equipped for conducting clinical trials, with highly trained staff, including full-time clinical coordinators and a laboratory technician. Dr. Saad's dedication to the field is matched by his passion for community outreach. He aims to improve the health outcomes in his local community, whether through comprehensive primary care, addiction treatment, or clinical research.



A. Saad, MD
Patient First Clinic

EDUCATION & EXPERIENCE

EDUCATION

FIELD OF EXPERIENCE

BOARD CERTIFICATIONS

Having earned his MD from Toledo School of Medicine and then completed his residency from William Beaumont Hospital, Michigan, Dr. Saad has over 10 years of experience in hospital and research settings.

Oakland University William Beaumont School of Medicine Residency, Internal Medicine, 2014


University of Toledo College of Medicine Medical School, 2011

Addiction Medicine, Internal Medicine & Obesity Medicine

Addiction Medicine
American Board of Preventive Medicine, 2019

Internal Medicine
American Board of Internal Medicine, 2014

Obesity Medicine
American Board of Obesity Medicine, 2023



**DR. ASAD
KARIM M.D.
30+ YEARS
YEARS OF EXPERIENCE**

SPECIALITY: CARDIOLOGY

Dr. Asad Karim is board-certified in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology. With advanced training from Loyola University and St. Louis University, he brings over 30 years of clinical experience, specializing in high-risk cardiovascular care—a critical area in vaccine and cardiac safety trials.

He has performed more than 15,000 diagnostic and interventional procedures, including angioplasty, cardiac imaging, and device implantation. His broad skill set supports precise oversight of studies involving patients with complex health profiles, ensuring reliable data and patient safety throughout the research process.

DEDICATION TO PATIENT CARE AND RESEARCH

Dr. Karim has consistently combined compassionate care with scientific precision throughout his career. His patient-first approach ensures that individuals participating in clinical trials receive thorough attention, clear communication, and comprehensive ethical oversight at every step.

He has contributed to numerous large-scale studies, including vaccine and cardiovascular trials, with a strong focus on safety, compliance, and data quality. His ability to balance clinical responsibilities with research rigor helps deliver outcomes that are both meaningful and reliable.

ROLE AT REVIVAL RESEARCH SITE INSTITUTE

At Revival Research Site Network, Dr. Asad Karim serves as a Principal Investigator, leading clinical trials with a focus on cardiovascular and vaccine-related research. Based in McKinney, Texas, he plays an essential role in ensuring protocol compliance, patient safety, and data integrity across all phases of study execution.

His leadership strengthens Revival's commitment to operational excellence and scientific advancement. Drawing from his extensive experience, Dr. Karim helps drive high-performing research teams and supports the successful delivery of complex, multi-site studies.

EDUCATION & EXPERIENCE

EDUCATION

FIELD OF EXPERIENCE

BOARD CERTIFICATIONS

With over three decades of clinical and academic experience, Dr. Asad Karim has established himself as a respected leader in cardiovascular and interventional medicine. His educational journey, post-graduate training, and board certifications reflect a deep commitment to excellence in both patient care and clinical research.

- **Dow Medical College, University of Karachi** – M.B.B.S., 1985
- **Loyola University Medical Center, Chicago, IL** – Internal Medicine Residency, 1986–1989
- **Loyola University Medical Center, Maywood, IL** – Cardiology Research Fellowship, 1989–1990
- **St. Louis University Medical Center, St. Louis, MO** – Cardiology Clinical Fellowship, 1990–1993
- **University of Nebraska Medical Center, Omaha, NE** – Assistant Professor, Interventional Cardiology

- Vaccine Studies
- Cardiovascular Disease
- Internal Medicine
- Clinical Research & Clinical Trials
- Vascular and Device-Based Therapies
- Internal Medicine
- Cardiovascular Disease
- Interventional Cardiology



THE WAY FORWARD

Revival Research Site Network is committed to advancing clinical research through innovation, collaboration, and community engagement. Our focus is on optimizing trial procedures, integrating cutting-edge technologies, and enhancing efficiency. We aim to increase diversity in clinical trials by 80% within the next year, expanding access to underrepresented communities while upholding the highest ethical standards.

**COMMITTED TO REDEFINING PATIENT CARE
ONE CLINICAL TRIAL AT A TIME**

For more information

📞 (248) 721-9539

✉️ info@rev-research.com